Ivabradine Accord

Ivabradine, the active ingredient in Ivabradine Accord, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina and heart failure with reduced ejection fraction, helping to lower heart rate in patients who remain symptomatic despite optimal therapy.

GNH USA supplies Ivabradine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate in specific cardiovascular conditions.

Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers heart rate, improves symptoms and may reduce hospitalisations.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Bradycardia - Visual disturbances (phosphenes) - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention - Atrial fibrillation or other arrhythmias - Severe hypotension - Worsening heart failure - Persistent visual loss or retinal abnormalities

Before initiating therapy, clinicians should assess cardiac status and potential drug interactions. - Heart rate monitoring: ensure resting heart rate remains above 60 bpm before starting. - Hepatic impairment: consider dose reduction in moderate liver dysfunction. - Concomitant bradycardic agents: avoid combining with beta‑blockers or digoxin without careful monitoring. - Contraindications: do not use in patients with sick‑sinus syndrome, acute decompensated heart failure, or severe hypotension. - Pregnancy and lactation: safety unknown; use only if benefits outweigh risks. - Store below 25°C: keep in the original pack, protect from moisture.

Ivabradine can interact with several medicines that affect heart rate or its metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase plasma levels. - Other If‑channel inhibitors – additive bradycardia risk. - Drugs that cause marked bradycardia (beta‑blockers, digoxin) – may lead to severe heart‑rate reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (rifampicin, carbamazepine) – may reduce efficacy. - Antihypertensives – monitor blood pressure and heart rate. - Diuretics affecting electrolytes – watch for arrhythmia risk. - Certain antiarrhythmics (e.g., amiodarone) – may require dose adjustment.